key: cord-1024874-0m18f1av authors: Faur, Rebeca; Irazoqui, Gustavo; Pavlovsky, Federico; Wikinski, Silvia title: EXPANDING ACCESSIBILITY: OUTPATIENT INTENSIVE TREATMENT FOR SUBSTANCE USE DISORDER DURING COVID19 PANDEMIC date: 2020-10-17 journal: Drug Alcohol Depend DOI: 10.1016/j.drugalcdep.2020.108359 sha: ce7dfa67eefdee53314ad590c6997f7f07501d56 doc_id: 1024874 cord_uid: 0m18f1av nan immediately before the beginning of the lockdown (T1-Adh) with that observed 3 months later (T2-Adh), using an 11 point scale (i.e. 0=absence of adherence and 10=the best performance). A single score for each patient at each time point was derived based upon two parameters: attendance at activities, and compliance (which included three items: use of a protocol agreed upon at the beginning of treatment, consistent use of an agenda together with cell phone applications to register sober time and general wellbeing, and compliance with other indications such as pharmacological treatment if prescribed). Alcohol and drug use were evaluated with the 5th version of the Addiction Severity Index (ASI) (4), comparing scores obtained at t h e time of admission to treatment (T0-alcohol or T0-drugs) to those measured immediately before the beginning of lockdown (T1-alcohol and T1-drugs) and three months later (T2-alcohol and T2drugs). The table summarizes the main demographic data of the 19 patients included in this report. There was no significant change over time in adherence scores (mean ± SD): T1-Adh: 8 ± 1.9 vs T2-Adh: 8 ± 1.4 (p = n.s.; Wilcoxon matched paired test, N = 19). ASI scores (mean ± SD) for alcohol and drug consumption improved over time: T0-alcohol: 0.30 ± 0.3; T1-alcohol 0.06 ± 0.12; T2-alcohol 0.02 ± 0.05 r (p < 0.001, Kruskal Wallis followed by Dunn's test; N = 19); T0-drugs 0.12 ± 0.1; T1-drugs 0.03 ± 0.05 and T2-drugs 0.001 ± 0.005 (p < 0.001; Kruskal Wallis followed by Dunn's test; N= 19). A slight increment in the drop-out/new admissions ratio was observed due to a decrement in admissions rather than an increment in drop-outs in the five months that elapsed after the pandemic onset, in comparison with a similar previous period (5/17 vs 5/20 respectively). These preliminary results suggest that a remotely-provided intensive outpatient treatment for people with SUD is as effective as a face-to-face ambulatory intensive approach, under the current extraordinary circumstances. However, it should be emphasized that the therapeutic team suffered significantly higher stress and work overload under these circumstances. To address this, in addition to the usual team meetings and clinical supervision, team members attended mutual support group meetings aimed at detecting individual cases of emotional distress, and providing support. According to our experience, sustaining outpatient programs during times of crisis such as the COVID-19 pandemic is not only possible, but necessary. The research on which this correspondence is based is partially supported by grants of University of Buenos Aires (UBACYT #20020170100017BA), National Council for Scientific and Technological Research from Argentina (PIP # 11220130100266CO). Funding was provided by governmental agencies and by University of Buenos Aires to SW, who is an independent researcher. RF, GI and FP equally participated in the recollection of data presented in this text. SW planned, and conducted the study and performed the statistics. RF and SW prepared the first draft of the manuscript. All the authors discussed the results and contributed to the final version. The psychological impact of quarantine and how to reduce it: rapid review of the evidence Collision of the COVID-19 and Addiction Epidemics The Fifth Edition of the Addiction Severity Index RF, GI and FP are part and receive payment from the private institution where the study is being performed. SW is an independent researcher, whose salaries are paid by the National Council for Scientific and Technological Research (Consejo Nacional de Investigaciones Científicas y Técnicas-CONICET) and the University of Buenos Aires, Argentina.